
|Articles|February 1, 2004
STAAR Surgical revamps procedures after FDA warning; product complaints at issue
Monrovia, CA-Officials at STAAR Surgical Co. are scrambling to answer questions raised by a warning letter from the FDA that criticized the company for failing to review product complaints adequately and ensure quality control of its manufacturing materials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Neurotrophic keratitis outcomes improve with early, stage-based care
5













































.png)


